Barclays raised the firm’s price target on Omada Health (OMDA) to $28 from $24 and keeps an Overweight rating on the shares ahead of the earnings report on November 6. The firm expects another “beat and raise” quarter based on seasonal trends, adoption of the company’s higher priced programs, growing GLP-1 use.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health’s Surge in App Downloads and GLP-1 Care Track Expansion Justify Buy Rating
- Omada Health added to ‘Tactical Outperform’ list at Evercore ISI
- Omada Health launches “Meal Map” AI-powered nutrition tool
- Omada Health announces analysis on weight maintenance post GLP-1 discontinuation
- Omada Health initiated with a Neutral at Baird